Literature DB >> 24997753

Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson's disease and Atypical Parkinsonian syndromes using DaTSCAN® SPECT.

Anette Davidsson1, Charalampos Georgiopoulos, Nil Dizdar, Göran Granerus, Helene Zachrisson.   

Abstract

OBJECTIVE: To verify if (123)I-FP-CIT, DaTSCAN(®) can differentiate early stages of Parkinson's disease (PD) as well as patients with Atypical Parkinsonian syndromes (APS) from manifest Parkinson's disease.
METHODS: 128 consecutive patients were investigated with (123)I-FP-CIT SPECT during a 4-year period. All patients were diagnosed according to the established consensus criteria for diagnosis of PD (n = 53) and APS (n = 19). Remaining patients were grouped early PD (before onset of L-DOPA medication), (n = 20), vascular PD (n = 6), and non-PD syndromes (n = 30) and SWEDD (n = 1). SPECT images were analyzed visually according to a predefined ranking scale of dopaminergic nerve cell degeneration, distinguishing a posterior-anterior degeneration pattern (egg shape) from a more global and severe degeneration pattern (burst striatum). Striatum uptake ratios were quantitatively analyzed with the 3D software, EXINI.
RESULTS: In the group of APS patients, the burst striatum pattern was most frequent and found in 61 % (11/18 patients). In PD patients, the egg shape pattern was dominating, especially in early PD where it was present in 95 % (19/20 patients). The positive predictive value for the egg shape pattern to diagnose PD was 92 % in this material (APS and all PD patients) and the specificity 90 % for the burst striatum pattern to exclude APS. The uptake ratios were reduced in both PD and APS patients and closely related to the image ranking.
CONCLUSION: In this study, we found that in more than half of the patients it was possible to differentiate between PD and APS by visual interpretation only. Similar results were obtained using semi-quantitative uptake ratios. Combining visual assessment with uptake ratios did not add to the discriminating power of DaTSCAN(®) SPECT in this material.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24997753     DOI: 10.1007/s12149-014-0878-x

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  10 in total

1.  The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes.

Authors:  Charalampos Georgiopoulos; Anette Davidsson; Maria Engström; Elna-Marie Larsson; Helene Zachrisson; Nil Dizdar
Journal:  J Neurol       Date:  2015-06-30       Impact factor: 4.849

2.  A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography.

Authors:  Ryota Bando; Hideki Otsuka; Tamaki Otani; Noritake Matsuda; Shota Azane; Yamato Kunikane; Yoichi Otomi; Wataru Sako; Yuishin Izumi; Masafumi Harada
Journal:  Ann Nucl Med       Date:  2021-02-25       Impact factor: 2.668

3.  Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases.

Authors:  Jun Ueda; Hajime Yoshimura; Keiji Shimizu; Megumu Hino; Nobuo Kohara
Journal:  Neurol Sci       Date:  2017-04-07       Impact factor: 3.307

4.  Establishing On-Site Reference Values for (123)I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions.

Authors:  Nicolas Nicastro; Valentina Garibotto; Antoine Poncet; Simon Badoud; Pierre R Burkhard
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

5.  Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome.

Authors:  G Martino; M Capasso; M Nasuti; L Bonanni; M Onofrj; A Thomas
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

6.  A new visual rating scale for Ioflupane imaging in Lewy body disease.

Authors:  Jim J Lloyd; George Petrides; Paul C Donaghy; Sean J Colloby; Johannes Attems; John T O'Brien; Gemma Roberts; Alan J Thomas
Journal:  Neuroimage Clin       Date:  2018-09-20       Impact factor: 4.881

Review 7.  Molecular Imaging of the Dopamine Transporter.

Authors:  Giovanni Palermo; Roberto Ceravolo
Journal:  Cells       Date:  2019-08-10       Impact factor: 6.600

8.  Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging.

Authors:  Enrico Premi; V D Calhoun; V Garibotto; R Turrone; A Alberici; E Cottini; A Pilotto; S Gazzina; M Magoni; B Paghera; B Borroni; A Padovani
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

9.  A study of neural activity and functional connectivity within the olfactory brain network in Parkinson's disease.

Authors:  Charalampos Georgiopoulos; Suzanne T Witt; Sven Haller; Nil Dizdar; Helene Zachrisson; Maria Engström; Elna-Marie Larsson
Journal:  Neuroimage Clin       Date:  2019-07-18       Impact factor: 4.881

10.  Improvement of classification performance of Parkinson's disease using shape features for machine learning on dopamine transporter single photon emission computed tomography.

Authors:  Takuro Shiiba; Yuki Arimura; Miku Nagano; Tenma Takahashi; Akihiro Takaki
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.